NHS National Generic Pharmaceuticals Wave 13

Description

Invitation to offer for NHS National Generic Pharmaceuticals Wave 13 Offer reference number: CM/PHG/17/5532 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months, with an option or options to extend (at the Authority's sole discretion) for a period or periods up to a total of 48 months. Potential periods of call-offs under the framework agreement: Transition (Everolimus) CESW: 1 March 2022 - 30 September 2023 (19 months) LSNE: 1 March 2022 - 31 January 2023 (11 months) NWLN: 1 March 2022 - 31 January 2023 (11 months) Oral Products plus non-parenterals All Regions: 1 March 2022 - 31 May 2024 (27 months) Hospital Only Products CESW: 1 February 2022 - 30 September 2023 (20 months) LSNE: 1 February 2022 - 31 May 2024 (28 months) NWLN: 1 February 2022 - 31 January 2023 (12 months)

Related Contracts